The ECHDC3 Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population, designed to disrupt the ECHDC3 gene in the NCI-H1975 human lung adenocarcinoma cell line. This product provides a heterogeneous pool of edited cells that collectively harbor targeted gene disruptions, enabling functional studies of ECHDC3 without clonal isolation. The polyclonal format preserves population diversity and mitigates the risk of clonal artifacts, making it suitable for pooled knockout studies, functional screens, and unbiased investigation of mitochondrial fatty acid metabolism.
The parental NCI-H1975 cell line is a widely used epithelial model of non-small cell lung cancer (NSCLC), derived from a human lung adenocarcinoma. It carries clinically relevant oncogenic mutations, specifically EGFR L858R/T790M and PIK3CA G118D, which drive proliferation and survival signaling. This genetic background establishes a disease-relevant context for exploring metabolic dependencies and therapeutic vulnerabilities in lung adenocarcinoma, particularly given the interplay between oncogenic signaling and metabolic reprogramming.
ECHDC3 encodes a mitochondrial enzyme that catalyzes the hydration and isomerization of enoyl-CoA intermediates during fatty acid beta-oxidation. As a core component of the mitochondrial beta-oxidation pathway, ECHDC3 interacts with key enzymes including HADHA, HADHB, ECHS1, and ACADVL to sustain efficient acyl-CoA processing. Its expression is transcriptionally regulated by PPARA and PPARGC1A, and modulated by metabolic sensors such as PRKAA1, SIRT1, and SREBF1. Downstream, ECHDC3 activity contributes to the production of acetyl-CoA, NADH, FADH2, and ATP, while influencing mitochondrial reactive oxygen species (ROS) levels. These molecular connections link ECHDC3 to the PPAR signaling pathway and broader mitochondrial energy homeostasis.
Disruption of ECHDC3 in the NCI-H1975 background impairs fatty acid oxidation, leading to reduced energy production from lipids and potential accumulation of lipid intermediates. Given the reliance of cancer cells on metabolic flexibility for proliferation and survival, this knockout model is particularly valuable for dissecting how NSCLC cells adapt to altered lipid metabolism. In the context of EGFR and PIK3CA mutations, the loss of ECHDC3 may expose synthetic lethal interactions or enhance sensitivity to metabolic inhibitors, offering a platform for identifying novel therapeutic strategies targeting metabolic reprogramming in lung cancer.
Researchers can employ these polyclonal knockout cells in a variety of functional assays, including Seahorse mitochondrial respiration analysis, fatty acid oxidation measurement, ATP quantification, lipid droplet staining, and ROS detection. The model supports investigations into drug sensitivity, cell proliferation, and changes in gene expression via RT-qPCR or Western blotting of pathway components such as ACAT1, ACADM, and ECHS1. Collectively, the ECHDC3 Knockout NCI-H1975 Polyclonal Cells provide a robust tool for studying mitochondrial beta-oxidation, metabolic adaptation, and therapeutic resistance in lung adenocarcinoma. For additional details or technical support, please contact Ascent Research.
